Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Becomes 1st Japan Drug Maker to Introduce Cryo-EM
June 1, 2021
- AstraZeneca Seeks Japan Approval for Tezepelumab in Severe Asthma
June 1, 2021
- Nipro Rolls Out Seven-Dose Syringe for Pfizer COVID-19 Vaccine
June 1, 2021
- Sanofi Introduces 1st NovoRapid Biosimilar in Japan
June 1, 2021
- Ayumi Curbs Enbrel Biosimilar Shipments in Fallout from Indian API Supply Disruption
June 1, 2021
- Pfizer Vaccine Now OK’ed for Adolescents, 1-Month Storage in Refrigerators
June 1, 2021
- Kobayashi Kako Submits Biz Improvement Plan Over Fudged Drug Filings
May 31, 2021
- EA Pharma/Kissei Seek Japan Approval of Ulcerative Colitis Drug
May 31, 2021
- AZ to Take Over Japan Synagis Rights from AbbVie in July as Global Pact Expires
May 31, 2021
- Yoshindo/Teijin Halt Enbrel Shipments as COVID-19 Stalls Indian API Supplies
May 31, 2021
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- Astellas Shoots for Annual 8% Growth through FY2025: 5-Year Plan
May 27, 2021
- Daiichi Sankyo’s Humira Biosimilar Now Available in Japan
May 27, 2021
- Takeda Stepping Up Work to Improve Japanese Ecosystem for Rare Diseases
May 27, 2021
- Sawai, Towa Post Domestic Sales Growth in FY2020, but Nichi-Iko Falters on GMP Violations: Jiho Tally
May 26, 2021
- Nihon Generic Recalling Ursodeoxycholic Acid Drug over Human Hair Contamination
May 25, 2021
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
- Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout
May 25, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…